Novartis bid to revive multiple sclerosis drug Gilenya patent rebuffed by US Supreme Court Ruchika Sharma18 April 2023 12:30 PM ISTThe USFDA in 2010 approved Gilenya to treat relapsing forms of multiple sclerosis.
Operating profit to grow again ahead of Sandoz spin off: Novartis Ruchika Sharma1 Feb 2023 10:00 AM ISTNovartis said in its statement it's on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its...
US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics Ruchika Sharma15 Oct 2022 1:30 PM ISTNovartis settled with some of the drugmakers it had sued, allowing for some Gilenya generics before a key patent's 2027 expiration.
Novartis to take US drug patent case to Supreme Court Ruchika Sharma22 Sept 2022 3:46 PM ISTZurich: Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug...
Whistleblower case alleging kickback for promotion of Novartis MS drug Gilenya dismissed Ruchika Sharma14 Sept 2022 2:30 PM ISTNovartis moved to dismiss, arguing that Camburn still had not offered enough detail to support his claim of a fraudulent scheme.
Setback to Novartis: US Court declares multiple sclerosis drug Gilenya patent invalid Ruchika Sharma22 Jun 2022 12:30 PM ISTNovartis also said it believes HEC and others cannot launch generic versions of Gilenya during the ongoing appeal process.
Novartis wins appeal over MS drug Gilenya patent: Bloomberg Medical Dialogues Bureau5 Jan 2022 10:00 AM ISTThe issue on appeal was whether the patent clearly explained the dosage regimen for fingolimod, the active ingredient in Gilenya, without the need for...
